I would guess that MRD with good prognosis wouldn't be enrolled in this trial to begin with
I thought that MRD in and of itself is a sign of poor prognosis post tx regardless of pre tx stratification based on various genetic or molecular markers (i.e. everyone with MRD is poor prognosis). I could be wrong. Regardless I do agree anyone w a good prognosis is probably not a candidate for this trial
In light of this response I think it's safe to say the drug successfully overcomes the antigen sink in peripheral blood and reaches the marrow. It could be though that you need debulking first to see responses but nevertheless still a positive IMO
The muted response in the stock to the data is probably the fact there was only one response out of 27 pts given monotherapy. But it still could be early to see responses in many of these patients, and the indications were very heterogeneous..
Market Data 
Markets 
AI
